Article: Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
PLoS medicine, 16(7):e1002851
2019
Abstract: SUMMARY POINTS: (*) Preclinical models of tuberculosis have significant limitations in selecting composition and duration of regimens for tuberculosis. (*) Innovative early-phase clinical trial methodologies and technologies have the potential to reduce ... ...
Abstract | SUMMARY POINTS: (*) Preclinical models of tuberculosis have significant limitations in selecting composition and duration of regimens for tuberculosis. (*) Innovative early-phase clinical trial methodologies and technologies have the potential to reduce risk and accelerate drug development in tuberculosis. (*) Phase IIA monotherapy studies are optional for proof of concept but may be useful for dose-finding in conjunction with pharmacokinetic–pharmacodynamic methods. (*) Innovative Phase IIB designs are increasingly common in tuberculosis drug development, utilising multiarm selection designs, sometimes in an adaptive format. (*) Novel biomarkers including liquid culture and nucleic acid amplification appear capable of replacing conventional solid culture in early-phase development. (*) Phase IIC and ultrashort noninferiority designs attempt to mitigate the problem of estimating duration of treatment regimens from Phase II results alone. |
---|---|
Keywords | Clinical trials ; Drug therapy ; Drug research and development ; Mycobacterium tuberculosis ; Phase II clinical investigation ; Phase III clinical investigation ; Toxicity ; Tuberculosis |
Language | English |
Document type | Article |
Database | Repository for Life Sciences |
Full text online
More links
Kategorien
Inter-library loan at ZB MED
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.